Eric L. Smith, MD, PhD
The advent of cellular therapy has invigorated the field of multiple myeloma, particularly for patients in the relapsed/refractory setting who have historically had a poor prognosis, according to Eric Smith, MD, PhD. However, he said, there is still more to accomplish regarding chimeric antigen receptor (CAR) T-cell therapy.
during the 2018 SOHO Annual Meeting, Smith, a medical oncologist at Memorial Sloan Kettering (MSK) Cancer Center, discussed the development of novel CAR T-cell therapies for patients with myeloma.
OncLive: What are some of the new developments in CAR T-cell therapy for patients with myeloma that you discussed in your presentation at the 2018 SOHO Annual Meeting?
: One of the most exciting advances in recent times for myeloma has been the advent of cellular therapy. We are seeing responses in patients who really have no other options, and a very limited prognosis. The responses so far to date do not seem durable in the majority of patients. I discussed ways to advance CAR T-cell therapy for myeloma with novel CAR T-cell vectors that may hopefully enhance the depth and persistence of responses to CAR T cells for those patients.
What are some of the products currently in the landscape? Which ones are coming down the pike?
bb2121 is the most advanced in terms of data that have been presented in the relapsed population and are being treated in US-based clinical trials. I have been involved in the development of JCARH125, which is also progressing in clinical trials now. The results have not been reported.
... to read the full story